Skip to main content
Premium Trial:

Request an Annual Quote

Decode s Revenues Drop 8 Percent, Losses Widen in Q1

NEW YORK, May 3 (GenomeWeb News) - Decode Genetics yesterday reported an 8-percent drop in revenues and a widened net loss for the first quarter of 2005.

 

Revenues for the quarter totaled $9.5 million, down from $10.3 million for the same period a year ago. This decrease reflects the company's new focus on drug discovery and development, according to Decode. The company said it also had $17.5 million in deferred research revenue on March 31, which it will recognize in future quarters.

 

Research and development costs almost doubled to $8.3 million from $4.3 milion during last year's first quarter. This increase results mainly from the cost of clinical trials of Decode's drug-development programs.

 

Decode's net loss widened to $16.9 million from $12 million during the year-ago quarter.

 

As of March 31, Decode had $197.6 million in cash, cash equivalents, and investments, including restricted cash.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.